Intra-Cellular Therapies, Inc.

Johnson & Johnson filed a supplemental new drug application (sNDA) with the US Food and Drug Administration for Caplyta (lumateperone) for the prevention of relapse in schizophrenia, part of the c

Summer is the time for sequels at the multiplex, and the biopharmaceutical sector offered a remake of its own as many of the datapoints for merger-and-acquisition activity during the second quarter ca

Sanofi is cementing its position as an immunology powerhouse by agreeing to acquire Blueprint Medicines Corp of the US and its soon-to-be blockbuster Ayvakit in a deal that could be worth up to $9.5bn

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso